BRCA-mutated triple-negative breast cancers are sensitive to platinum agents. The randomized phase 2 INFORM trial sought to detect an improvement in pathologic complete response (pCR) rate with neoadjuvant cisplatin compared to standard doxorubicin-cyclophosphamide (AC) chemo for HER2(-) disease. Over 100 BRCA-mutation carriers with stage I-III breast cancer (including 45% N+) were enrolled. The pCR rate was not significantly better—not even close—with cisplatin (18%) compared to AC (26%). When looking at a slightly less stringent measure of low residual tumor burden, standard AC still won out. This held true when looking just at the TNBC (70%) or the ER(+) (30%) cohort. TBL: AC remains the backbone of systemic therapy for HER2(-) breast cancer, even among BRCA-carriers. | Tung, J Clin Oncol 2020


Popular Posts